Genetic Predisposition to Neuroleptic Malignant Syndrome: Implications for Antipsychotic Therapy

Author： Kawanishi C.  

Publisher： Adis International

ISSN： 1175-2203

Source： American Journal of PharmacoGenomics, Vol.3, Iss.2, 2003-01, pp. : 89-95

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Neuroleptic Malignant Syndrome Associated with Atypical Antipsychotic Drugs

By Trollor Julian N.   Chen Xiaohua   Sachdev Perminder S.  

CNS Drugs, Vol. 23, Iss. 6, 2009-05 ,pp. : 477-492

Adis International

Access to resources Recommend Favorite

Antidepressants and neuroleptic malignant syndrome

By Assion H.J.   Heinemann F.   Laux G.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 293-293

Elsevier

Access to resources Recommend Favorite

Identification and Treatment of Neuroleptic Malignant Syndrome

By  

Child and Adolescent Psychopharmacology News, Vol. 6, Iss. 3, 2001-06 ,pp. : 1-6

Guilford Publications Inc

Access to resources Recommend Favorite

Pharmacogenetic Aspects of Neuroleptic Malignant Syndrome

By  

Current Pharmacogenomics, Vol. 4, Iss. 2, 2006-01 ,pp. : 113-119

Bentham Science Publishers

Access to resources Recommend Favorite

Neuropsychotherapeutics: Neuroleptic malignant syndrome during combination therapy and possible topiramate overdose: case report

By  

Reactions Weekly, Vol. 1, Iss. 1158, 2007-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite